Work

Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment

Year: 2015

Type: article

Abstract: A 1999 investigation1 found that industry sponsorship of cost-effectiveness analyses (CEAs) for oncology drugs was associated with lower likelihood of reporting unfavorable conclusions relative to CEAs with other sponsorship. Over the past 15 years, the CEA literature for oncology drugs has expanded dramatically, and oncology now accounts for the largest single pharmaceutical sales area worldwide.2 We sought to determine whether the association between industry sponsorship and CEA results has persisted.

Source: JAMA Oncology

DOI: 10.1001/jamaoncol.2015.3928

Authors: Jordan D. Lane, Mark W. Friedberg, Charles L. Bennett

Institutions: Walter Reed National Military Medical Center, Brigham and Women's Hospital, University of South Carolina

Language: English

Topic: Pharmaceutical industry and healthcare

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute